Pfizer Splits Into 3 Segments In Latest Shakeup

Law360, New York (July 29, 2013, 3:18 PM EDT) -- Pfizer Inc. on Monday said it would shuffle its internal operations to create new business segments focused on brand-name and generic drugs, the latest shakeup for the pharmaceutical giant and a possible precursor to a formal splitting up of the company.

The reorganization will result in three new lines — one devoted to generics and two focused on branded products. One of the branded divisions will be home to therapies involving inflammation, metabolism, neuroscience, pain, rare diseases and gender-specific health, and the other will encompass vaccines,...
To view the full article, register now.